Covishield COVID-19 vaccine safety monitoring and surveillance finding report from March 22, 2021 to June 20, 2021 in Ethiopia

Abstract

In response to SARS-CoV-2 (COVID-19) pandemic, vaccines were developed and deployed for use. EFDA conducted post market adverse events monitoring on the authorized AstraZeneca’s COVID-19 vaccine (Covishield). This report provides a summary of the type and extent of adverse events following immunization (AEFIs). AEFIs described in this report are defined as any untoward medical occurrences that are followed immunization and do not necessarily have a causal relationship with the vaccine